Treatment of Hirsutism With a Gonadotropin-Releasing Hormone Agonist (Nafarelin)

Andreyko, Janice L.; Monroe, Scott M.; Jaffe, Robert B.

doi:10.1016/s0022-5347(17)44406-5

Cited by 3 publications

(8 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Others have reported a decrease in circulating iLH levels after 2 to 4 weeks of GnRH agonist treatment (Andreyko et al, 1986;Calogero et al, 1987;Couzinet et al, 1986;Mongioi et al, 1986). While a difference in the potency of the agonists or in the dosage used could explain the discrepancy with our results, most probably it could be due to the RIA used.…”

Section: Discussioncontrasting

confidence: 95%

“…Andreyko reported no LH or FSH acute responses after 2 weeks of twice daily intranasal administration of 500 pg of Nafarelin (Andreyko et al, 1986). Andreyko reported no LH or FSH acute responses after 2 weeks of twice daily intranasal administration of 500 pg of Nafarelin (Andreyko et al, 1986).…”

Section: Discussionmentioning

confidence: 99%

“…Immunoreactive LH (iLH) has been shown either to be decreased (Andreyko et al, 1986;Couzinet et al, 1986;Calogero et al, 1987), to be unchanged (Faure & Lemay, 1987) or to be increased (Chang et al, 1983;De Fazio et al, 1985) compared to pretreatment levels. A number of analogues have been used at different dosages and various patterns of gonadotrophin suppression Correspondence: Nacia Faure, Endocrinologie de la Reproduction et &Infertilit&, HBpital St-FranGois d'Assise, 10, rue de I'Espinay, Quebec, Canada, GIL 3L5 have been described.…”

mentioning

confidence: 99%

“…A number of analogues have been used at different dosages and various patterns of gonadotrophin suppression Correspondence: Nacia Faure, Endocrinologie de la Reproduction et &Infertilit&, HBpital St-FranGois d'Assise, 10, rue de I'Espinay, Quebec, Canada, GIL 3L5 have been described. Immunoreactive LH (iLH) has been shown either to be decreased (Andreyko et al, 1986;Couzinet et al, 1986;Calogero et al, 1987), to be unchanged (Faure & Lemay, 1987) or to be increased (Chang et al, 1983;De Fazio et al, 1985) compared to pretreatment levels. On the other hand, FSH has been shown to be decreased in most cases, with only occasional absence of modification of the circulating concentrations.…”

mentioning

confidence: 99%

See 3 more Smart Citations

Acute Pituitary‐ovarian Response During Chronic Luteinizing Hormone‐releasing Hormone Agonist Administration in Polycystic Ovarian Syndrome

Faure

Lemay

1988

Clinical Endocrinology

View full text Add to dashboard Cite

The purpose of the study was to evaluate the acute effect of daily subcutaneous injections of the GnRH agonist Buserelin on serum concentration of LH (evaluated by radioimmunoassay (iLH), and by bioassay (bioLH], FSH, oestradiol and testosterone in 20 women with a diagnosis of polycystic ovarian disease (PCO). Buserelin was administered subcutaneously at the dose of 200 micrograms three times daily for 7 days followed by 500 micrograms once daily for a total treatment period of 6 months. Blood samples were drawn immediately before and 2, 4 and 6 h after the injection on the first day of treatment as well as after 1, 2, 3, 4, 12 and 24 weeks. The first injection of Buserelin induced statistically significant rises of iLH, bioLH and FSH as well as of 17 beta-oestradiol. The acute response of gonadotrophins was suppressed after 1 week but a partial recuperation of FSH and iLH responses was observed starting after 2 and 4 weeks of treatment. No significant acute changes of bioLH or of 17 beta-oestradiol and testosterone could be seen. The persistence of a small but statistically significant pituitary response in the first hours following the daily injection of the peptide suggests a hyper-reactive state of the gonadotrophs in PCO patients. Such acute pituitary responses are not seen when a similar treatment is administered to endocrinologically normal women. This observation could be an argument in favour of an initial central defect in the pathogenesis of the syndrome.

show abstract

Section: Discussioncontrasting

confidence: 95%

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

mentioning

confidence: 99%

See 2 more Smart Citations

Acute Pituitary‐ovarian Response During Chronic Luteinizing Hormone‐releasing Hormone Agonist Administration in Polycystic Ovarian Syndrome

Faure

Lemay

1988

Clinical Endocrinology

View full text Add to dashboard Cite

show abstract

“…With continuous administration, superactive GnRH analogues suppress LH and FSH secretion and thus reduce LH‐mediated androgen secretion 47–52 . GnRH analogues suppress ovarian hormone secretion to a greater degree than the OCP alone and would therefore be expected to be more effective 47 .…”

Section: Pharmacological Treatmentmentioning

confidence: 99%

Managing hirsutism in gynaecological practice

Conn

Jacobs

1998

BJOG

View full text Add to dashboard Cite

Ovarian Suppression in Polycystic Ovarian Disease During 6 Month Administration of a Luteinizing Hormone‐releasing Hormone (Lh‐rh) Agonist

Faure

Lemay

1987

Clinical Endocrinology

View full text Add to dashboard Cite

This study was designed to evaluate the long-term effect (6 months) of the luteinizing hormone-releasing hormone (LH-RH) agonist buserelin on pituitary and ovarian function in a group of 14 patients presenting with the polycystic ovarian (PCO) syndrome. Buserelin was given subcutaneously 200 micrograms three times daily for the first 7 days followed by 500 micrograms once daily. Blood samples were taken weekly for the first month and then every month for radioimmunoassay of LH, FSH and sex steroids. While LH levels were stimulated during the first 2 weeks and then declined towards baseline, serum FSH levels were reduced after only 1 week (P less than 0.05). Serum oestradiol levels were maximally suppressed to the menopausal range after 1 month and testosterone levels were also significantly inhibited (P less than 0.05) after 2 weeks of therapy. Dehydroepiandrosterone (DHEA) sulphate did not show any significant change while 17-hydroxyprogesterone was suppressed after the first month of buserelin administration (P less than 0.01). The apparent divergent response of the gonadotrophins and the reduction of ovarian steroids in spite of lack of suppression of LH levels can be explained by the marked inhibition of the bioactivity of LH assessed by dispersed mouse Leydig cells assay. The clinical evaluation of hirsutism did not detect any change during the 6 month period. No patient had any menstrual bleeding or spotting after the sixth week of buserelin. The monthly incidence of hot flushes varied between 50 to 66%. This study shows that LH-RH agonist administration can selectively inhibit ovarian function and could be an interesting approach to evaluate the respective contribution of the ovary and adrenal on the pathophysiology of the polycystic ovarian disease. Polycystic ovarian (PCO) syndrome is characterized by tonic and exaggerated secretion of LH leading to an excessive stimulation of the ovarian stroma and an increased production of androgens (Yen et al., 1970; DeVane et al., 1975; Rebar et al., 1976). The androgen precursor delta 4 androstenedione is transformed in peripheral tissues into oestrone (Siiteri & MacDonald, 1973), thus maintaining the state of pituitary hypersensitivity and creating a positive feedback (Yen et al., 1976). The starting point of this vicious circle is still controversial; some argue for a hypothalamic abnormality (Vaitukaitis, 1983) while others support the peripheral origin of the hypersecretion of steroids (Reyniak, 1983). The importance of the adrenal contribution in this syndrome is still unclear.(ABSTRACT TRUNCATED AT 400 WORDS)

show abstract

Treatment of Hirsutism With a Gonadotropin-Releasing Hormone Agonist (Nafarelin)

Cited by 3 publications

References 0 publications

Acute Pituitary‐ovarian Response During Chronic Luteinizing Hormone‐releasing Hormone Agonist Administration in Polycystic Ovarian Syndrome

Acute Pituitary‐ovarian Response During Chronic Luteinizing Hormone‐releasing Hormone Agonist Administration in Polycystic Ovarian Syndrome

Managing hirsutism in gynaecological practice

Ovarian Suppression in Polycystic Ovarian Disease During 6 Month Administration of a Luteinizing Hormone‐releasing Hormone (Lh‐rh) Agonist

Contact Info

Product

Resources

About